Develops treatments for endocrine disorders and rare diseases, focusing on innovative therapies for pediatric and adult patients.
Spruce Biosciences, Inc. is a pioneering biopharmaceutical firm specializing in the development and advancement of innovative therapies tailored for rare endocrine disorders. Central to its mission, the company is actively involved in the development of tildacerfont, a non-steroidal therapy designed to optimize disease management and minimize steroid dependency in adult patients afflicted with congenital adrenal hyperplasia (CAH). Currently, tildacerfont is undergoing Phase 2b clinical trials aimed at assessing its efficacy in reducing glucocorticoid requirements and improving clinical outcomes in adults with classic CAH.
Beyond adult populations, Spruce Biosciences is expanding its research to include pediatric classic congenital adrenal hyperplasia, with tildacerfont undergoing Phase 2 clinical trials specifically tailored for children. Additionally, the company is exploring the potential of tildacerfont as a treatment option for females with polycystic ovary syndrome, also in Phase 2 clinical trials. These initiatives underscore Spruce Biosciences' commitment to addressing critical unmet medical needs in endocrinology through innovative therapeutic approaches.
Established in 2014 and headquartered in Daly City, California, Spruce Biosciences, Inc. operates with a strategic license agreement with Eli Lilly and Company. This partnership facilitates collaborative efforts in the research, development, and commercialization of pharmaceutical compounds across diverse therapeutic applications, reinforcing the company's position at the forefront of advancing treatments for rare endocrine disorders.